Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
NVIDIA's CEO Jensen Huang indicates that Chinese regulatory approval for the sale of its flagship H200 AI chip is still pending, amid high demand from major tech firms and ongoing U.S.-China tech tensions.
As Bangladesh heads to the polls on February 12 under an interim government, its geopolitical alignments are shifting. The outcome will test the influence of regional powers India, China, and Pakistan in a nation navigating a post-Hasina political landscape.
Hong Kong apparel giant Crystal International is investing in a high-tech logistics center in China, aiming to slash fabric transfer times by 75% and power operations with solar energy as part of its broader smart manufacturing push.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Russian Security Council Secretary Sergei Shoigu, meeting with China's top diplomat Wang Yi in Moscow, reiterated Russia's firm support for Beijing's position on Taiwan, calling it an 'inseparable part' of China. The talks underscore deepening strategic coordination between the two powers amid global tensions.
A private gauge of China's manufacturing activity edged higher in January, defying expectations of a slowdown, as export-oriented firms outperformed. The reading contrasts with weaker official data, highlighting a two-speed industrial sector amid persistent domestic headwinds.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
China's factory activity unexpectedly contracted in January, official data shows, reversing a brief December expansion and underscoring persistent domestic demand challenges despite robust exports.
Prime Minister Keir Starmer confirmed during his Beijing visit that China has removed sanctions against six UK MPs and peers, a move signaling a diplomatic reset after years of tension over human rights concerns.
A.O. Smith's Q4 2025 earnings reveal a tale of two stories: revenue that missed expectations but profits that beat them. The water technology leader is leaning into commercial strength and operational discipline to expand margins, even as it braces for a challenging 2026 marked by input cost inflation and persistent softness in its China business.
The global apparel manufacturer is launching a state-of-the-art logistics center in China, featuring a fully automated closed-loop material flow system. The facility aims to slash fabric transfer times by up to 75%, optimize inventory, and advance the company's 2030 sustainability goals through solar power and waste-reduction technologies.
Yum China Holdings, the operator of KFC and Pizza Hut in China, is considering initiating a quarterly dividend, signaling a potential shift toward more regular capital returns to shareholders amid strong analyst sentiment.
BHP Group achieves a key milestone with full autonomy at its Escondida Norte copper pit, boosting safety and efficiency for its strategic copper expansion. Meanwhile, the miner contends with the commercial impact of China's ongoing ban on iron ore from its Jimblebar operation, forcing a reshuffle of global sales channels.
In a significant diplomatic gesture, China has agreed to remove travel restrictions on a group of sanctioned British lawmakers, Prime Minister Keir Starmer revealed following talks with President Xi Jinping. The move comes during the first UK leader's visit to China in eight years, aimed at thawing bilateral relations.
